Niraparib as Maintenance Therapy in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Inclusion Criteria: * Female participants 18 years old or older. * Participant must be able to understand the study procedures and agree to participate in the study by providing written informed consent. * Participant must have received niraparib within the Spanish expanded access program (EAP). * Patients must have received at least 1 week of treatment with niraparib. * Histological diagnosis of high grade serous ovarian cancer, fallopian tube cancer, or primary peritoneal cancer. * Participants must have completed at least 2 previous courses of platinum-containing therapy (e.g., carboplatin, oxaliplatin, or cisplatin). * For the penultimate (next to last) platinum-based chemotherapy course prior to enrolment on the program the patient must have platinum sensitive disease after this treatment; defined as achieving a response (complete response (CR) or partial response (PR)) and disease progression occurring no sooner than 6 months, after completion of the last dose of platinum chemotherapy. * For the last chemotherapy course prior to inclusion in the program the patient must have received a platinum-containing regimen for a minimum of 4 cycles. * For the last chemotherapy course prior to inclusion in the program the Patient must have achieved a partial (PR) or complete (CR) tumor response. * The last platinum regimen does not necessarily have to immediately follow the next to last (penultimate) platinum regimen. For example, if a patient received a non-platinum regimen between the penultimate platinum regimen and last platinum regimen, they could be eligible, so long as they meet all entry criteria. * When entering the EAP, patients must have met the following: * Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. * Adequate organ function - Absolute neutrophil count (ANC) ≥ (greater than or equal to) 1,500/μL. * Adequate organ function - Platelets ≥ (greater than or equal to) 100,000/μL. * Adequate organ function - Hemoglobin ≥ (greater than or equal to) 9 g/dL. * No transfusions of erythrocytes or platelets within 2 weeks prior to assessing adequate hematological blood counts as listed above. Exclusion Criteria: * Patients without medical record available (lost, empty or unretrievable clinical information). * Patients who decline consent. * Patients who are deceased with prior express order to preserve their data.